[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Rilpivirine.]
[L04AA27, fingolimod, The metabolism of Fingolimod can be decreased when combined with Rilpivirine.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Rilpivirine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Rilpivirine.]
[M04AB02, sulfinpyrazone, The serum concentration of Rilpivirine can be decreased when it is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sulpiride.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Rilpivirine.]
[L02BA01, tamoxifen, The serum concentration of Rilpivirine can be decreased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Rilpivirine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Rilpivirine.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Rilpivirine.]
[G03BA03, testosterone, The serum concentration of Rilpivirine can be decreased when it is combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Rilpivirine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Rilpivirine.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Rilpivirine.]
[L04AX02, thalidomide, The serum concentration of Rilpivirine can be decreased when it is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Rilpivirine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Rilpivirine.]
[N05CA19, thiopental, The serum concentration of Rilpivirine can be decreased when it is combined with Thiopental.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Rilpivirine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Rilpivirine.]
[B01AC05, ticlopidine, The metabolism of Rilpivirine can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Rilpivirine.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Rilpivirine.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Rilpivirine.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Rilpivirine.]
[N06AF04, tranylcypromine, The metabolism of Rilpivirine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Rilpivirine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Rilpivirine.]
[S01BA05, triamcinolone, The serum concentration of Rilpivirine can be decreased when it is combined with Triamcinolone.]
[R03BA07, mometasone, The serum concentration of Rilpivirine can be decreased when it is combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Rilpivirine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Rilpivirine.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Rilpivirine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Rilpivirine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Rilpivirine.]
[J01FA08, troleandomycin, The serum concentration of Rilpivirine can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Rilpivirine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Rilpivirine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Rilpivirine.]
[A10BH05, linagliptin, The metabolism of Rilpivirine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Rilpivirine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Rilpivirine can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Rilpivirine.]
[B01AF01, rivaroxaban, Rilpivirine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Rilpivirine.]
[C08DA01, verapamil, The serum concentration of Rilpivirine can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The serum concentration of Rilpivirine can be increased when it is combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Rilpivirine can be decreased when it is combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Rilpivirine.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Rilpivirine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Rilpivirine.]
[S01AA13, fusidic acid, The metabolism of Rilpivirine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Rilpivirine can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rilpivirine.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Rilpivirine.]
[L01ED01, crizotinib, The serum concentration of Rilpivirine can be increased when it is combined with Crizotinib.]
[R03DC01, zafirlukast, The serum concentration of Rilpivirine can be increased when it is combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rilpivirine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Rilpivirine.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Rilpivirine.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Rilpivirine.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Rilpivirine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Rilpivirine.]
[J02AC03, voriconazole, The metabolism of Rilpivirine can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Rilpivirine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Rilpivirine.]
[H02AB11, prednylidene, The serum concentration of Rilpivirine can be decreased when it is combined with Prednylidene.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Rilpivirine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Rilpivirine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Rilpivirine.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Rilpivirine can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Rilpivirine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Rilpivirine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Rilpivirine.]
[L04AA31, teriflunomide, Rilpivirine may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Rilpivirine.]
[N05CA04, barbital, The serum concentration of Rilpivirine can be decreased when it is combined with Barbital.]
[J05AE04, nelfinavir, The serum concentration of Rilpivirine can be increased when it is combined with Nelfinavir.]
[N06DA02, donepezil, Rilpivirine may decrease the excretion rate of Donepezil which could result in a higher serum level.]
[N03AX22, perampanel, The serum concentration of Rilpivirine can be decreased when it is combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Rilpivirine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Rilpivirine.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Rilpivirine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Rilpivirine.]
[G04BE03, sildenafil, The metabolism of Rilpivirine can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Rilpivirine.]
[B01AF02, apixaban, Rilpivirine may decrease the excretion rate of Apixaban which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Rilpivirine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Rilpivirine.]
[A16AX09, glycerol phenylbutyrate, The serum concentration of Rilpivirine can be decreased when it is combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Rilpivirine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Rilpivirine.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Rilpivirine can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Moxifloxacin.]
[A06AX06, tegaserod, Rilpivirine may decrease the excretion rate of Tegaserod which could result in a higher serum level.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Rilpivirine.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Rilpivirine.]
[M01AH01, celecoxib, Rilpivirine may decrease the excretion rate of Celecoxib which could result in a higher serum level.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Rilpivirine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Rilpivirine.]
[L01EC02, dabrafenib, The serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The serum concentration of Rilpivirine can be decreased when it is combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Rilpivirine.]
[L01EB03, afatinib, Rilpivirine may decrease the excretion rate of Afatinib which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Rilpivirine.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bepridil.]
[C02KX05, riociguat, Rilpivirine may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Rilpivirine.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Rilpivirine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Rilpivirine.]
[N03AF04, eslicarbazepine, The serum concentration of Rilpivirine can be decreased when it is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Rilpivirine can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Rilpivirine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Rilpivirine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Rilpivirine.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Rilpivirine.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Rilpivirine.]
[A16AA07, metreleptin, The metabolism of Rilpivirine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Rilpivirine can be increased when combined with Apremilast.]
[L02BG02, formestane, The serum concentration of Rilpivirine can be decreased when it is combined with Formestane.]
[S03BA03, betamethasone, The serum concentration of Rilpivirine can be decreased when it is combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Rilpivirine.]
[L04AC11, siltuximab, The serum concentration of Rilpivirine can be decreased when it is combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Rilpivirine.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Rilpivirine.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Rilpivirine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Rilpivirine.]
[L01EM01, idelalisib, The serum concentration of Rilpivirine can be increased when it is combined with Idelalisib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Olodaterol.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Rilpivirine.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Rilpivirine.]
[J01XA05, oritavancin, The serum concentration of Rilpivirine can be decreased when it is combined with Oritavancin.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Rilpivirine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Rilpivirine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Rilpivirine.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Rilpivirine.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Rilpivirine.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Rilpivirine.]
[L04AC10, secukinumab, The metabolism of Rilpivirine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Rilpivirine.]
[L01EX08, lenvatinib, Rilpivirine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Rilpivirine.]
[N02BE01, acetaminophen, The serum concentration of Rilpivirine can be increased when it is combined with Acetaminophen.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Rilpivirine can be decreased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Rilpivirine.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Rilpivirine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Rilpivirine.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Rilpivirine.]
[J02AC05, isavuconazole, The serum concentration of Rilpivirine can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Rilpivirine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Rilpivirine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Rilpivirine.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Rilpivirine.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Rilpivirine.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Rilpivirine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Rilpivirine.]
[M04AB05, lesinurad, The serum concentration of Rilpivirine can be decreased when it is combined with Lesinurad.]
[J05AP11, grazoprevir, The excretion of Grazoprevir can be decreased when combined with Rilpivirine.]
[N05CA05, aprobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Aprobarbital.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Rilpivirine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Rilpivirine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07AC11, amcinonide, The serum concentration of Rilpivirine can be decreased when it is combined with Amcinonide.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Rilpivirine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Rilpivirine.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Rilpivirine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Rilpivirine.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Rilpivirine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Rilpivirine.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Rilpivirine.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Rilpivirine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Arsenic trioxide.]
[P01BE02, artemether, The serum concentration of Rilpivirine can be decreased when it is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sparfloxacin.]
[R06AX09, azatadine, The serum concentration of Rilpivirine can be decreased when it is combined with Azatadine.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Rilpivirine.]
[L01XK03, rucaparib, Rilpivirine may decrease the excretion rate of Rucaparib which could result in a higher serum level.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Rilpivirine can be decreased when combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Rilpivirine.]
[D05AX03, calcitriol, The serum concentration of Rilpivirine can be decreased when it is combined with Calcitriol.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AE09, tipranavir, The serum concentration of Rilpivirine can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Rilpivirine.]
[L04AB02, infliximab, The metabolism of Rilpivirine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of Rilpivirine can be decreased when it is combined with Midostaurin.]
[L01ED04, brigatinib, The serum concentration of Rilpivirine can be decreased when it is combined with Brigatinib.]
[L04AC14, sarilumab, The serum concentration of Rilpivirine can be decreased when it is combined with Sarilumab.]
[J01MA23, delafloxacin, The serum concentration of Rilpivirine can be decreased when it is combined with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Rilpivirine.]
[L01XX59, enasidenib, The serum concentration of Rilpivirine can be decreased when it is combined with Enasidenib.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Rilpivirine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Rilpivirine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Rilpivirine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Rilpivirine.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AG03, efavirenz, The serum concentration of Rilpivirine can be decreased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Rilpivirine.]
[R03BA02, budesonide, The serum concentration of Rilpivirine can be decreased when it is combined with Budesonide.]
[L01EL02, acalabrutinib, The serum concentration of Rilpivirine can be increased when it is combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Rilpivirine can be increased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, Rilpivirine may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Rilpivirine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Rilpivirine can be decreased when it is combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Rilpivirine.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Rilpivirine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Rilpivirine.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Rilpivirine.]
[H01CC03, elagolix, The serum concentration of Rilpivirine can be decreased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Rilpivirine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Rilpivirine.]
[N03AX17, stiripentol, The metabolism of Rilpivirine can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Rilpivirine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Rilpivirine can be decreased when combined with Tecovirimat.]
[L01EM04, duvelisib, Rilpivirine may decrease the excretion rate of Duvelisib which could result in a higher serum level.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Rilpivirine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Rilpivirine.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Rilpivirine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Rilpivirine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Inotersen.]
[L01XK04, talazoparib, Rilpivirine may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Rilpivirine.]
[R03BB08, revefenacin, Rilpivirine may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The serum concentration of Rilpivirine can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Rilpivirine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Rilpivirine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Rilpivirine.]
[P02BX04, triclabendazole, The metabolism of Rilpivirine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The serum concentration of Rilpivirine can be decreased when it is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Rilpivirine.]
[J01FA09, clarithromycin, The serum concentration of Rilpivirine can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Rilpivirine.]
[N05BA09, clobazam, The serum concentration of Rilpivirine can be decreased when it is combined with Clobazam.]
[H02AB14, cloprednol, The serum concentration of Rilpivirine can be decreased when it is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Rilpivirine.]
[L04AB01, etanercept, The metabolism of Rilpivirine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The serum concentration of Rilpivirine can be decreased when it is combined with Cortivazol.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Rilpivirine.]
[L02BB06, darolutamide, Rilpivirine may decrease the excretion rate of Darolutamide which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Rilpivirine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Cicletanine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Rilpivirine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Rilpivirine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Rilpivirine.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Rilpivirine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Rilpivirine.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Rilpivirine.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Rilpivirine.]
[J01DB09, cephradine, The serum concentration of Rilpivirine can be decreased when it is combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Rilpivirine can be decreased when it is combined with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Rilpivirine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Rilpivirine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Rilpivirine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Rilpivirine.]
[N03AX25, cenobamate, The serum concentration of Rilpivirine can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Rilpivirine.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Rilpivirine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Rilpivirine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Rilpivirine.]
[L01XX72, tazemetostat, Rilpivirine may decrease the excretion rate of Tazemetostat which could result in a higher serum level.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Rilpivirine.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Rilpivirine.]
[J05AB16, remdesivir, The serum concentration of Rilpivirine can be increased when it is combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Rilpivirine.]
[H02CA02, osilodrostat, The serum concentration of Rilpivirine can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Rilpivirine can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, Rilpivirine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, Rilpivirine may decrease the excretion rate of Selumetinib which could result in a higher serum level.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Rilpivirine.]
[N02CC06, eletriptan, The serum concentration of Rilpivirine can be decreased when it is combined with Eletriptan.]
[M01AH02, rofecoxib, The serum concentration of Rilpivirine can be decreased when it is combined with Rofecoxib.]
[L01XF03, bexarotene, The serum concentration of Rilpivirine can be decreased when it is combined with Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Rilpivirine can be decreased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Rilpivirine.]
[S03AA08, chloramphenicol, The metabolism of Rilpivirine can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Rilpivirine.]
[D07XB03, fluprednidene, The serum concentration of Rilpivirine can be decreased when it is combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Rilpivirine.]
[L01EX19, ripretinib, Rilpivirine may decrease the excretion rate of Ripretinib which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Rilpivirine can be increased when it is combined with Selpercatinib.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Rilpivirine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Rilpivirine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ebastine.]
[J05AX29, fostemsavir, Rilpivirine may decrease the excretion rate of Fostemsavir which could result in a higher serum level.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Rilpivirine.]
[L01FX15, belantamab mafodotin, The excretion of Belantamab mafodotin can be decreased when combined with Rilpivirine.]
[L04AC19, satralizumab, The serum concentration of Rilpivirine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Rilpivirine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Rilpivirine.]
[L01EX23, pralsetinib, The serum concentration of Rilpivirine can be increased when it is combined with Pralsetinib.]
[D01AE07, chlorphenesin, The serum concentration of Rilpivirine can be decreased when it is combined with Chlorphenesin.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Rilpivirine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Rilpivirine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Rilpivirine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Rilpivirine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Rilpivirine.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Rilpivirine.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Rilpivirine.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Rilpivirine.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Rilpivirine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Relugolix.]
[P03AX07, abametapir, The serum concentration of Rilpivirine can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, Rilpivirine may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N03AX10, felbamate, The serum concentration of Rilpivirine can be decreased when it is combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Flumequine.]
[R03BA03, flunisolide, The serum concentration of Rilpivirine can be decreased when it is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The serum concentration of Rilpivirine can be decreased when it is combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Rilpivirine.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Rilpivirine.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Rilpivirine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Rilpivirine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Rilpivirine.]
[S03AA07, ciprofloxacin, The serum concentration of Rilpivirine can be increased when it is combined with Ciprofloxacin.]
[N06AB04, citalopram, Rilpivirine may increase the QTc-prolonging activities of Citalopram.]
[H01AC07, somapacitan, The metabolism of Rilpivirine can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Rilpivirine.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Rilpivirine is combined with Fexinidazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Rilpivirine.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Rilpivirine.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Rilpivirine.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Rilpivirine.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Rilpivirine.]
[N06AX25, St. John's wort extract, The serum concentration of Rilpivirine can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Rilpivirine can be decreased when combined with Asciminib.]
[D07AD01, clobetasol, The serum concentration of Rilpivirine can be decreased when it is combined with Clobetasol.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Rilpivirine.]
[J04BA01, clofazimine, The serum concentration of Rilpivirine can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The serum concentration of Rilpivirine can be decreased when it is combined with Clofibrate.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Rilpivirine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Rilpivirine.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Rilpivirine.]
[C01EB24, mavacamten, The serum concentration of Rilpivirine can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The absorption of Rilpivirine can be decreased when combined with Vonoprazan.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Rilpivirine.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Rilpivirine.]
[G01AF02, clotrimazole, The serum concentration of Rilpivirine can be decreased when it is combined with Clotrimazole.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Granisetron.]
[L01XX77, adagrasib, The serum concentration of Rilpivirine can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The serum concentration of Rilpivirine can be decreased when it is combined with Clozapine.]
[D07AC12, halometasone, The serum concentration of Rilpivirine can be decreased when it is combined with Halometasone.]
[H01AC08, somatrogon, The metabolism of Rilpivirine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Rilpivirine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Rilpivirine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Rilpivirine.]
[L04AA13, leflunomide, Rilpivirine may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Rilpivirine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Rilpivirine.]
[J01FA15, telithromycin, The serum concentration of Rilpivirine can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Rilpivirine can be decreased when it is combined with Ciclesonide.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Desloratadine.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Rilpivirine.]
[H01AX01, pegvisomant, The serum concentration of Rilpivirine can be decreased when it is combined with Pegvisomant.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Rilpivirine.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Rilpivirine.]
[J02AC02, itraconazole, The serum concentration of Rilpivirine can be increased when it is combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Rilpivirine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Rilpivirine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Rilpivirine.]
[S01BA03, cortisone, The serum concentration of Rilpivirine can be decreased when it is combined with Cortisone.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Rilpivirine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lomefloxacin.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Rilpivirine can be decreased when combined with Manidipine.]
[S01BA08, medrysone, The serum concentration of Rilpivirine can be decreased when it is combined with Medrysone.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Rilpivirine.]
[H02AB15, meprednisone, The serum concentration of Rilpivirine can be decreased when it is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Rilpivirine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Rilpivirine.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Melperone.]
[L01AA01, cyclophosphamide, The serum concentration of Rilpivirine can be decreased when it is combined with Cyclophosphamide.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Rilpivirine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Rilpivirine.]
[N06AG02, moclobemide, The metabolism of Rilpivirine can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The serum concentration of Rilpivirine can be decreased when it is combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Rilpivirine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Rilpivirine.]
[C10AA07, rosuvastatin, Rilpivirine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Rilpivirine can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Rilpivirine.]
[M01AH05, etoricoxib, The metabolism of Rilpivirine can be decreased when combined with Etoricoxib.]
[L01DA01, dactinomycin, Rilpivirine may decrease the excretion rate of Dactinomycin which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Rilpivirine can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Rilpivirine.]
[L01DB02, daunorubicin, The serum concentration of Rilpivirine can be decreased when it is combined with Daunorubicin.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Rilpivirine.]
[G03XX01, prasterone, The serum concentration of Rilpivirine can be increased when it is combined with Prasterone.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Rilpivirine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Rilpivirine.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Rilpivirine.]
[N06AX06, nefazodone, The serum concentration of Rilpivirine can be increased when it is combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Rilpivirine can be decreased when combined with Nilutamide.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Rilpivirine.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Rilpivirine.]
[S01BA11, desonide, The serum concentration of Rilpivirine can be decreased when it is combined with Desonide.]
[L01XA03, oxaliplatin, Rilpivirine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The serum concentration of Rilpivirine can be decreased when it is combined with Oxcarbazepine.]
[G01AF17, oxiconazole, The serum concentration of Rilpivirine can be decreased when it is combined with Oxiconazole.]
[S03BA01, dexamethasone, The serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Rilpivirine.]
[L04AB04, adalimumab, The metabolism of Rilpivirine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Rilpivirine may decrease the excretion rate of Gefitinib which could result in a higher serum level.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Rilpivirine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Rilpivirine.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Rilpivirine.]
[N06AB05, paroxetine, The serum concentration of Rilpivirine can be increased when it is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Rilpivirine.]
[N05BA01, diazepam, The metabolism of Rilpivirine can be decreased when combined with Diazepam.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Rilpivirine.]
[J01CF01, dicloxacillin, The serum concentration of Rilpivirine can be decreased when it is combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Rilpivirine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Rilpivirine.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Rilpivirine.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Rilpivirine.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Rilpivirine.]
[C08CA03, isradipine, The metabolism of Rilpivirine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The serum concentration of Rilpivirine can be decreased when it is combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Rilpivirine.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Rilpivirine.]
[C10AX09, ezetimibe, Rilpivirine may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Rilpivirine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Rilpivirine.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Rilpivirine.]
[J05AE08, atazanavir, The serum concentration of Rilpivirine can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Rilpivirine.]
[D07AC18, prednicarbate, The serum concentration of Rilpivirine can be decreased when it is combined with Prednicarbate.]
[C08DB01, diltiazem, The serum concentration of Rilpivirine can be increased when it is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Rilpivirine can be decreased when combined with Dimethyl sulfoxide.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Rilpivirine.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rilpivirine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Rilpivirine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Rilpivirine.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Rilpivirine.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Rilpivirine.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Rilpivirine.]
[S02AA12, rifamycin SV, The serum concentration of Rilpivirine can be decreased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Rilpivirine can be decreased when it is combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rilpivirine can be decreased when it is combined with Rifaximin.]
[N07XX02, riluzole, Rilpivirine may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Rilpivirine.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Rilpivirine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Rilpivirine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Rilpivirine.]
[A04AD12, aprepitant, The metabolism of Rilpivirine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Rilpivirine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Rilpivirine.]
[J05AE07, fosamprenavir, The serum concentration of Rilpivirine can be increased when it is combined with Fosamprenavir.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Rilpivirine.]
[C02KX02, ambrisentan, The excretion of Ambrisentan can be decreased when combined with Rilpivirine.]
[C01EB18, ranolazine, The serum concentration of Rilpivirine can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rilpivirine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Rilpivirine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Rilpivirine.]
[N06AA12, doxepin, Doxepin can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Rilpivirine.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Rilpivirine.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Rilpivirine.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be decreased when combined with Rilpivirine.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Droperidol.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Rilpivirine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sultopride.]
[N02CC01, sumatriptan, Rilpivirine may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Talinolol.]
[H01AA01, corticotropin, The serum concentration of Rilpivirine can be decreased when it is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Rilpivirine.]
[D01BA02, terbinafine, The serum concentration of Rilpivirine can be decreased when it is combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Rilpivirine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Rilpivirine.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Rilpivirine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Rilpivirine.]
[N03AX11, topiramate, The serum concentration of Rilpivirine can be decreased when it is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Rilpivirine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Rilpivirine.]
[N01AB04, enflurane, The metabolism of Enflurane can be decreased when combined with Rilpivirine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Rilpivirine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Rilpivirine.]
[S01GX10, epinastine, Epinastine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Rilpivirine.]
[C08CA12, mepirodipine, The metabolism of Rilpivirine can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Rilpivirine.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Rilpivirine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Rilpivirine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Rilpivirine.]
[N02CA02, ergotamine, The metabolism of Rilpivirine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Rilpivirine.]
[S01AA17, erythromycin, The serum concentration of Rilpivirine can be increased when it is combined with Erythromycin.]
[A02BC02, pantoprazole, The therapeutic efficacy of Rilpivirine can be decreased when used in combination with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Rilpivirine.]
[G03CA57, estrogens, conjugated (USP), Rilpivirine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Rilpivirine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The serum concentration of Rilpivirine can be decreased when it is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The serum concentration of Rilpivirine can be decreased when it is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Rilpivirine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Rilpivirine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Rilpivirine.]
[N03AB01, ethotoin, The serum concentration of Rilpivirine can be decreased when it is combined with Ethotoin.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Rilpivirine.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Rilpivirine.]
[L01CB01, etoposide, The serum concentration of Rilpivirine can be decreased when it is combined with Etoposide.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Rilpivirine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Rilpivirine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Rilpivirine.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Rilpivirine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Rilpivirine.]
[R06AX12, terfenadine, The serum concentration of Rilpivirine can be decreased when it is combined with Terfenadine.]
[N06AX12, bupropion, The serum concentration of Bupropion can be increased when it is combined with Rilpivirine.]
[N06AB08, fluvoxamine, The serum concentration of Rilpivirine can be increased when it is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Rilpivirine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Leuprolide.]
[C10AA03, pravastatin, Rilpivirine may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Rilpivirine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Rilpivirine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Rilpivirine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Rilpivirine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rilpivirine.]
[L01BB06, clofarabine, Rilpivirine may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, Rilpivirine may decrease the excretion rate of Cladribine which could result in a higher serum level.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Rilpivirine.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Rilpivirine.]
[J01CF05, floxacillin, The serum concentration of Rilpivirine can be decreased when it is combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Rilpivirine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Rilpivirine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Rilpivirine.]
[D07AC08, fluocinonide, The serum concentration of Rilpivirine can be decreased when it is combined with Fluocinonide.]
[H02AB03, fluocortolone, The serum concentration of Rilpivirine can be decreased when it is combined with Fluocortolone.]
[V03AZ01, ethanol, The serum concentration of Rilpivirine can be decreased when it is combined with Ethanol.]
[S01CB05, fluorometholone, The serum concentration of Rilpivirine can be decreased when it is combined with Fluorometholone.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Rilpivirine.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Rilpivirine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Flupentixol.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Rilpivirine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fluspirilene.]
[V04CX02, folic acid, Rilpivirine may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Rilpivirine.]
[J05AE10, darunavir, The serum concentration of Rilpivirine can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Rilpivirine.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Rilpivirine.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Rilpivirine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gallopamil.]
[N03AA04, barbexaclone, The serum concentration of Rilpivirine can be decreased when it is combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Rilpivirine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Rilpivirine.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Rilpivirine.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Rilpivirine.]
[J05AG04, etravirine, The serum concentration of Rilpivirine can be decreased when it is combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Rilpivirine.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Rilpivirine.]
[A10BB01, glyburide, Rilpivirine may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Rilpivirine.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Rilpivirine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Rilpivirine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Rilpivirine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Rilpivirine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Rilpivirine.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Rilpivirine.]
[D01BA01, griseofulvin, The serum concentration of Rilpivirine can be decreased when it is combined with Griseofulvin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Haloperidol.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Rilpivirine.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Rilpivirine.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Rilpivirine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Rilpivirine.]
[M04AA01, allopurinol, Rilpivirine may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Rilpivirine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Rilpivirine.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Rilpivirine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Rilpivirine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Rilpivirine.]
[C08CA10, nilvadipine, The metabolism of Rilpivirine can be decreased when combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Rilpivirine.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Rilpivirine.]
[S02BA01, hydrocortisone, The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.]
[D07AC16, hydrocortisone aceponate, The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone aceponate.]
[D07AB11, hydrocortisone probutate, The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone probutate.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Rilpivirine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Hydroxyzine.]
[J04AB04, rifabutin, The serum concentration of Rilpivirine can be decreased when it is combined with Rifabutin.]
[S01BA13, rimexolone, The serum concentration of Rilpivirine can be decreased when it is combined with Rimexolone.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Rilpivirine.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Rilpivirine.]
[L01AA06, ifosfamide, The serum concentration of Rilpivirine can be decreased when it is combined with Ifosfamide.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Rilpivirine.]
[L01CD01, paclitaxel, The serum concentration of Rilpivirine can be decreased when it is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Rilpivirine.]
[L01CE01, topotecan, Rilpivirine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Rilpivirine.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be decreased when combined with Rilpivirine.]
[N06AX17, milnacipran, The metabolism of Rilpivirine can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Rilpivirine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Rilpivirine.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Rilpivirine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Rilpivirine.]
[C10AA06, cerivastatin, The serum concentration of Rilpivirine can be decreased when it is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Rilpivirine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Rilpivirine.]
[N01AB06, isoflurane, The metabolism of Isoflurane can be decreased when combined with Rilpivirine.]
[J04AC01, isoniazid, The metabolism of Rilpivirine can be decreased when combined with Isoniazid.]
[P02CF01, ivermectin, Rilpivirine may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The serum concentration of Rilpivirine can be decreased when it is combined with Tocilizumab.]
[N01AX03, ketamine, The serum concentration of Rilpivirine can be decreased when it is combined with Ketamine.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Rilpivirine.]
[J02AB02, ketoconazole, The serum concentration of Ketoconazole can be decreased when it is combined with Rilpivirine.]
[H02CA04, levoketoconazole, The serum concentration of Rilpivirine can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AC03, deferasirox, The serum concentration of Rilpivirine can be decreased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Rilpivirine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Rilpivirine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Rilpivirine.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Rilpivirine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Rilpivirine.]
[A05AA02, ursodiol, The serum concentration of Rilpivirine can be decreased when it is combined with Ursodeoxycholic acid.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Rilpivirine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lidoflazine.]
[N06BA13, armodafinil, The serum concentration of Rilpivirine can be decreased when it is combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Rilpivirine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Rilpivirine.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Rilpivirine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Rilpivirine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Rilpivirine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Rilpivirine.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, Rilpivirine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Rilpivirine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Rilpivirine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Rilpivirine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Rilpivirine.]
[N06DX01, memantine, The metabolism of Rilpivirine can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Rilpivirine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Rilpivirine.]
[N03AA01, mephobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Methylphenobarbital.]
[L02BG01, aminoglutethimide, The serum concentration of Rilpivirine can be decreased when it is combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Rilpivirine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Paliperidone.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Rilpivirine.]
[N07BC02, methadone, The serum concentration of Methadone can be decreased when it is combined with Rilpivirine.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Rilpivirine.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H03BB02, methimazole, The metabolism of Rilpivirine can be decreased when combined with Methimazole.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Rilpivirine.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Rilpivirine.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Rilpivirine.]
[V04CG05, methylene blue, The serum concentration of Rilpivirine can be increased when it is combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Rilpivirine.]
[H02AB04, methylprednisolone, The serum concentration of Rilpivirine can be decreased when it is combined with Methylprednisolone.]
[N03AF03, rufinamide, The serum concentration of Rilpivirine can be decreased when it is combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Rilpivirine.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Rilpivirine.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rilpivirine.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be decreased when combined with Rilpivirine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Rilpivirine.]
[V04CD01, metyrapone, The serum concentration of Rilpivirine can be decreased when it is combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Rilpivirine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Rilpivirine.]
[S02AA13, miconazole, The metabolism of Rilpivirine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Rilpivirine.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Rilpivirine.]
[G03XB01, mifepristone, The serum concentration of Rilpivirine can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Rilpivirine.]
[L01XX23, mitotane, The serum concentration of Rilpivirine can be decreased when it is combined with Mitotane.]
[L01DB07, mitoxantrone, Rilpivirine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Rilpivirine.]
[C01BD01, amiodarone, The serum concentration of Rilpivirine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Rilpivirine.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Rilpivirine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Rilpivirine.]
[L04AB05, certolizumab pegol, The metabolism of Rilpivirine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Rilpivirine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Rilpivirine.]
[N05CA02, amobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Rilpivirine.]
[G03XC01, raloxifene, Rilpivirine may decrease the excretion rate of Raloxifene which could result in a higher serum level.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Rilpivirine.]
[N03AB05, fosphenytoin, The serum concentration of Rilpivirine can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Rilpivirine.]
[J01CF06, nafcillin, The serum concentration of Rilpivirine can be decreased when it is combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Rilpivirine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Rilpivirine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Rilpivirine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Rilpivirine.]
[A10BG01, troglitazone, The serum concentration of Rilpivirine can be decreased when it is combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Rilpivirine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Rilpivirine.]
[L02BG04, letrozole, The metabolism of Rilpivirine can be decreased when combined with Letrozole.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Rilpivirine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Rilpivirine.]
[N06AX23, desvenlafaxine, The metabolism of Rilpivirine can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Rilpivirine can be decreased when combined with Telmisartan.]
[C08CA04, nicardipine, The serum concentration of Rilpivirine can be increased when it is combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Rilpivirine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Rilpivirine.]
[N07BA01, nicotine, The metabolism of Nicotine can be decreased when combined with Rilpivirine.]
[C08CA05, nifedipine, The serum concentration of Rilpivirine can be decreased when it is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Nimodipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Rilpivirine.]
[J01XE01, nitrofurantoin, Rilpivirine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Rilpivirine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Rilpivirine.]
[C02KX01, bosentan, The serum concentration of Rilpivirine can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Rilpivirine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rilpivirine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Rilpivirine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Rilpivirine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Rilpivirine.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Rilpivirine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Rilpivirine.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Rilpivirine.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Rilpivirine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rilpivirine.]
[N05AH05, asenapine, Asenapine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Rilpivirine can be decreased when it is combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Rilpivirine.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Rilpivirine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Rilpivirine.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Penfluridol.]
[M01CC01, penicillamine, The excretion of Penicillamine can be decreased when combined with Rilpivirine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Rilpivirine.]
[N05CA01, pentobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Pentobarbital.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Rilpivirine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Rilpivirine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Rilpivirine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Rilpivirine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Rilpivirine.]
[N03AA02, phenobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Rilpivirine.]
[M02AA01, phenylbutazone, The serum concentration of Rilpivirine can be decreased when it is combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB02, phenytoin, The serum concentration of Rilpivirine can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Rilpivirine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Rilpivirine.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Rilpivirine.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Rilpivirine.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be increased when it is combined with Rilpivirine.]
[J05AE01, saquinavir, The serum concentration of Rilpivirine can be increased when it is combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Rilpivirine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Rilpivirine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Rilpivirine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Rilpivirine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Rilpivirine.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Rilpivirine.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Rilpivirine.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Rilpivirine.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Rilpivirine.]
[L04AC08, canakinumab, The metabolism of Rilpivirine can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Rilpivirine can be increased when it is combined with Ritonavir.]
[C10AA08, pitavastatin, Rilpivirine may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Rilpivirine.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Rilpivirine.]
[C02CA01, prazosin, Rilpivirine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The serum concentration of Rilpivirine can be decreased when it is combined with Prednisolone.]
[H02AB07, prednisone, The serum concentration of Rilpivirine can be decreased when it is combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Rilpivirine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Rilpivirine can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The serum concentration of Rilpivirine can be decreased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Rilpivirine.]
[C10AB05, fenofibrate, The metabolism of Rilpivirine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Rilpivirine.]
[G03DA04, progesterone, The serum concentration of Rilpivirine can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Rilpivirine.]
[R06AD02, promethazine, Promethazine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Rilpivirine.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Rilpivirine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Rilpivirine.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Rilpivirine.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Rilpivirine.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Rilpivirine.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Rilpivirine.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Rilpivirine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Rilpivirine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Rilpivirine.]
[C01BA01, quinidine, The serum concentration of Rilpivirine can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Rilpivirine can be decreased when it is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02AA02, reserpine, The serum concentration of Rilpivirine can be decreased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Rilpivirine can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Roxithromycin.]
[A07EC01, sulfasalazine, Rilpivirine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Rilpivirine.]
[N05CA06, secobarbital, The serum concentration of Rilpivirine can be decreased when it is combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Rilpivirine.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Rilpivirine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Rilpivirine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Rilpivirine.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone butyrate.]
[S01GX11, alcaftadine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alcaftadine.]
[S02DA03, antipyrine, Antipyrine may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01GA01, streptomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Streptomycin.]
[A02BX02, sucralfate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sucralfate.]
[J01CG01, sulbactam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulbactam.]
[J01EC02, sulfadiazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Tenofovir alafenamide can be increased when combined with Sulfinpyrazone.]
[M01AB02, sulindac, Sulindac may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N03AX03, sulthiame, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Sulthiame.]
[M01AX04, apazone, Azapropazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01BB02, mercaptopurine, The excretion of Tenofovir alafenamide can be decreased when combined with Mercaptopurine.]
[L02BA01, tamoxifen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Temazepam.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Tenofovir alafenamide.]
[R03CC03, terbutaline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Testosterone.]
[S03AA02, tetracycline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may increase the nephrotoxic activities of Tenofovir alafenamide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Tenofovir alafenamide.]
[P02CA02, thiabendazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Thiabendazole.]
[R06AD03, thiethylperazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Tenofovir alafenamide.]
[N05CA19, thiopental, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Thiopental.]
[G04BE06, moxisylyte, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Moxisylyte.]
[N05AL03, tiapride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tiapride.]
[B01AC05, ticlopidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ticlopidine.]
[S01ED01, timolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Timolol.]
[P01AB02, tinidazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tinidazole.]
[S01AA12, tobramycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tobramycin.]
[A10BB05, tolazamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tolazamide.]
[V04CA01, tolbutamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tolbutamide.]
[M02AA21, tolmetin, Tolmetin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N02AX02, tramadol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tramadol.]
[N06AX05, trazodone, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Trazodone.]
[S01BA05, triamcinolone, The metabolism of Tenofovir alafenamide can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N05CD05, triazolam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Triazolam.]
[A16AX12, trientine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Triethylenetetramine.]
[S01AD02, trifluridine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trifluridine.]
[S01BA09, clobetasone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clobetasone.]
[R03BA07, mometasone, The metabolism of Tenofovir alafenamide can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trimebutine.]
[N03AC02, trimethadione, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Trimethadione.]
[J01EA01, trimethoprim, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trimethoprim.]
[J01FA08, troleandomycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Roflumilast.]
[L01FX04, ipilimumab, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ipilimumab.]
[L01EX04, vandetanib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oxyquinoline.]
[A10BH05, linagliptin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Tenofovir alafenamide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Telaprevir.]
[S01AA28, vancomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vancomycin.]
[N03AX21, ezogabine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Ezogabine.]
[B01AF01, rivaroxaban, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rivaroxaban.]
[B01AC24, ticagrelor, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Tenofovir alafenamide.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Tenofovir alafenamide.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Tenofovir alafenamide.]
[B03BA01, vitamin B12, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cyanocobalamin.]
[A11HA03, vitamin E, The metabolism of Tenofovir alafenamide can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Warfarin.]
[J05AF01, zidovudine, The excretion of Tenofovir alafenamide can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Tenofovir alafenamide can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Tenofovir alafenamide can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Tenofovir alafenamide.]
[M05BA05, tiludronic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tiludronic acid.]
[B06AC02, icatibant, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Icatibant.]
[L01ED01, crizotinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Tenofovir alafenamide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Ibandronate.]
[N05AE04, ziprasidone, The metabolism of Tenofovir alafenamide can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Tenofovir alafenamide can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Deferiprone.]
[N02BA01, aspirin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ruxolitinib.]
[G04BD07, tolterodine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tolterodine.]
[J01DH04, doripenem, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Doripenem.]
[J02AC03, voriconazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Auranofin.]
[L01XJ01, vismodegib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vismodegib.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Tenofovir alafenamide.]
[R07AX02, ivacaftor, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ivacaftor.]
[G02AD03, gemeprost, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gemeprost.]
[H02AB11, prednylidene, The metabolism of Tenofovir alafenamide can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Peginesatide.]
[L01BC07, azacitidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Azacitidine.]
[L04AX01, azathioprine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Azathioprine.]
[L01BC05, gemcitabine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gemcitabine.]
[J01DF01, aztreonam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Aztreonam.]
[R02AB04, bacitracin, Bacitracin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tenofovir alafenamide.]
[M03BX01, baclofen, Tenofovir alafenamide may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Tenofovir alafenamide.]
[A08AA11, lorcaserin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Carfilzomib.]
[L02BB04, enzalutamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Tenofovir alafenamide.]
[L04AA31, teriflunomide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Teriflunomide.]
[L01EX05, regorafenib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Barbital.]
[D02BA02, octinoxate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Octinoxate.]
[J05AE04, nelfinavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nelfinavir.]
[N04BD02, rasagiline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rasagiline.]
[N03AX22, perampanel, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Perampanel.]
[V09IX04, fluorodeoxyglucose F18, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fludeoxyglucose (18F).]
[H01CB05, pasireotide, The metabolism of Tenofovir alafenamide can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gadofosveset trisodium.]
[L01EA05, ponatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ponatinib.]
[A16AX08, teduglutide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Teduglutide.]
[C10AX12, lomitapide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lomitapide.]
[A10BH04, alogliptin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pomalidomide.]
[N02BA10, benorilate, Benorilate may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A10BK02, canagliflozin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.]
[M04AB03, benzbromarone, The excretion of Tenofovir alafenamide can be decreased when combined with Benzbromarone.]
[J02AX04, caspofungin, The excretion of Tenofovir alafenamide can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ancestim.]
[M01AH01, celecoxib, Celecoxib may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L04AA18, everolimus, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Benzydamine.]
[L01EE01, trametinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trametinib.]
[V09AX05, florbetapir F-18, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Florbetapir (18F).]
[L01EB03, afatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The excretion of Tenofovir alafenamide can be decreased when combined with Dolutegravir.]
[A10BJ03, lixisenatide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lixisenatide.]
[A05AA03, cholic acid, The excretion of Tenofovir alafenamide can be decreased when combined with Cholic Acid.]
[C02KX04, macitentan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Macitentan.]
[N06AX26, vortioxetine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vortioxetine.]
[G03AC08, etonogestrel, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Etonogestrel.]
[N03AF04, eslicarbazepine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Simeprevir.]
[N03AG04, vigabatrin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Vigabatrin.]
[C01CA27, droxidopa, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Droxidopa.]
[N05CH03, tasimelteon, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Tenofovir alafenamide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Apremilast.]
[L02BG02, formestane, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Tenofovir alafenamide can be increased when combined with Betamethasone.]
[V03AB34, fomepizole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fomepizole.]
[C10AB02, bezafibrate, The excretion of Tenofovir alafenamide can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Tenofovir alafenamide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Tenofovir alafenamide.]
[B01AC26, vorapaxar, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Tenofovir alafenamide.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Tenofovir alafenamide.]
[N07XX08, tafamidis, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tafamidis.]
[V08AA01, diatrizoic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Diatrizoate.]
[V08AA04, iothalamic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Diatrizoate.]
[N05CM19, suvorexant, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Tenofovir alafenamide can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EX09, nintedanib, The metabolism of Tenofovir alafenamide can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Gentamicin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J05AP09, dasabuvir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Tenofovir alafenamide.]
[B01AF03, edoxaban, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Tenofovir alafenamide can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Tenofovir alafenamide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The excretion of Tenofovir alafenamide can be decreased when combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Tenofovir alafenamide.]
[J05AP07, daclatasvir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acetaminophen.]
[L01DC01, bleomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bleomycin.]
[J05AF08, adefovir dipivoxil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Tenofovir alafenamide can be decreased when combined with Eluxadoline.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Tenofovir alafenamide.]
[A04AD14, rolapitant, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flibanserin.]
[M02AA25, aceclofenac, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Aceclofenac.]
[M01AB11, acemetacin, Acemetacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S01EC01, acetazolamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Acetazolamide.]
[A02BC03, lansoprazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lansoprazole.]
[V03AB37, idarucizumab, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Idarucizumab.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Tenofovir alafenamide.]
[J02AC05, isavuconazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Osimertinib.]
[S01AA13, fusidic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fusidic acid.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Tenofovir alafenamide.]
[L01XG03, ixazomib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ixazomib.]
[L01ED03, alectinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alectinib.]
[M04AB05, lesinurad, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The metabolism of Tenofovir alafenamide can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N03AX23, brivaracetam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Brivaracetam.]
[L01XX52, venetoclax, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bromazepam.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Almasilate.]
[N05AX17, pimavanserin, The metabolism of Tenofovir alafenamide can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bumetanide.]
[N01BB01, bupivacaine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levobupivacaine.]
[N07BC01, buprenorphine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Buprenorphine.]
[N05BE01, buspirone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Tenofovir alafenamide.]
[L01XX27, arsenic trioxide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rabeprazole.]
[L01XK03, rucaparib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Tenofovir alafenamide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A06AH05, naldemedine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Naldemedine.]
[N07XX16, deutetrabenazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Pregabalin.]
[N03AX30, beclamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Beclamide.]
[N06BC01, caffeine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Caffeine.]
[D05AX03, calcitriol, The metabolism of Tenofovir alafenamide can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Benznidazole.]
[J01XX08, linezolid, The excretion of Tenofovir alafenamide can be decreased when combined with Linezolid.]
[J05AF06, abacavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Abacavir.]
[J05AE09, tipranavir, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Tenofovir alafenamide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Tenofovir alafenamide can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Brigatinib.]
[N04BD03, safinamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Safinamide.]
[L04AC14, sarilumab, The metabolism of Tenofovir alafenamide can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Delafloxacin.]
[D01AC10, bifonazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Neratinib.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Tenofovir alafenamide.]
[L01EF03, abemaciclib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Abemaciclib.]
[C07AB07, bisoprolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Tenofovir alafenamide can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may increase the nephrotoxic activities of Tenofovir alafenamide.]
[V03AB23, acetylcysteine, The excretion of Tenofovir alafenamide can be decreased when combined with Acetylcysteine.]
[R03BA02, budesonide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Budesonide.]
[M01AB07, bumadizone, Bumadizone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Tenofovir alafenamide.]
[S01EE06, latanoprostene bunod, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Latanoprostene bunod.]
[J05AX18, letermovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Letermovir.]
[N01BX04, capsaicin, The metabolism of Tenofovir alafenamide can be decreased when combined with Capsaicin.]
[R06AX18, acrivastine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acrivastine.]
[C09AA01, captopril, The excretion of Tenofovir alafenamide can be decreased when combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Carbamazepine.]
[J01CA03, carbenicillin, The excretion of Tenofovir alafenamide can be decreased when combined with Carbenicillin.]
[C07AG02, carvedilol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fostamatinib.]
[N03AX24, cannabidiol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD10, cefetamet, Cefetamet may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD09, cefodizime, Cefodizime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DC11, ceforanide, Ceforanide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD13, cefpodoxime, Cefpodoxime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD14, ceftibuten, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ceftibuten.]
[J01GB14, plazomicin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Plazomicin.]
[H01CC03, elagolix, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Tenofovir alafenamide can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Migalastat.]
[N03AX17, stiripentol, The metabolism of Tenofovir alafenamide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Tenofovir alafenamide can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Tenofovir alafenamide.]
[L01EB07, dacomitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sarecycline.]
[S01GX12, cetirizine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cetirizine.]
[D08AE05, chloroxylenol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chloroxylenol.]
[M01AC05, lornoxicam, Lornoxicam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N07XX15, inotersen, Inotersen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01ED05, lorlatinib, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Tenofovir alafenamide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Carmustine.]
[L01EX13, gilteritinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glasdegib.]
[A06AX05, prucalopride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Prucalopride.]
[B01AC23, cilostazol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Tenofovir alafenamide can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Tenofovir alafenamide.]
[J01FA09, clarithromycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Solriamfetol.]
[N06AX29, brexanolone, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Brexanolone.]
[L01EN01, erdafitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Tenofovir alafenamide can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The excretion of Tenofovir alafenamide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Tenofovir alafenamide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Tenofovir alafenamide can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Tenofovir alafenamide.]
[J01DC04, cefaclor, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefaclor.]
[J01DB05, cefadroxil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefadroxil.]
[J01DC03, cefamandole, Cefamandole may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XX66, selinexor, The excretion of Tenofovir alafenamide can be decreased when combined with Selinexor.]
[J01DB07, cefatrizine, Cefatrizine may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DB04, cefazolin, Cefazolin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L02BB06, darolutamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DC06, cefonicid, Cefonicid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Tenofovir alafenamide.]
[J01DD12, cefoperazone, Cefoperazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD01, cefotaxime, Cefotaxime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DC05, cefotetan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefotetan.]
[J01DC07, cefotiam, Cefotiam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DC01, cefoxitin, Cefoxitin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD03, cefsulodin, Cefsulodin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD02, ceftazidime, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ceftazidime.]
[J01DD07, ceftizoxime, Ceftizoxime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DD04, ceftriaxone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ceftriaxone.]
[S01AA27, cefuroxime, Cefuroxime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EJ02, fedratinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Tenofovir alafenamide can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Tenofovir alafenamide.]
[N04CX01, istradefylline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The excretion of Tenofovir alafenamide can be decreased when combined with Cyclothiazide.]
[J01XX09, daptomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DB03, cephalothin, Cefalotin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DB08, cephapirin, Cefapirin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DB09, cephradine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Tenofovir alafenamide can be increased when combined with Deflazacort.]
[N02CC08, lasmiditan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Tenofovir alafenamide.]
[N03AX25, cenobamate, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may increase the nephrotoxic activities of Tenofovir alafenamide.]
[M09AX08, golodirsen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Golodirsen.]
[S01XA12, dexpanthenol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexpanthenol.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Tenofovir alafenamide.]
[C10AX15, bempedoic acid, The excretion of Tenofovir alafenamide can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The metabolism of Tenofovir alafenamide can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Tenofovir alafenamide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Tenofovir alafenamide can be decreased when combined with Amprenavir.]
[R02AA03, dichlorobenzyl alcohol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dichlorobenzyl alcohol.]
[G03DB08, dienogest, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dienogest.]
[M01AH02, rofecoxib, Rofecoxib may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XF03, bexarotene, The metabolism of Tenofovir alafenamide can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Valpromide.]
[J01FA13, dirithromycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Tenofovir alafenamide can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Tenofovir alafenamide.]
[L01EX17, capmatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Tenofovir alafenamide can be increased when combined with Fluprednidene.]
[M01AC04, droxicam, Droxicam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EX19, ripretinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mangafodipir.]
[M02AA27, dexketoprofen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Clomethiazole.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Tenofovir alafenamide.]
[J05AX29, fostemsavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fostemsavir.]
[L04AC19, satralizumab, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The excretion of Tenofovir alafenamide can be decreased when combined with Chlorothiazide.]
[N05AA01, chlorpromazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chlorpropamide.]
[M03BB03, chlorzoxazone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chlorzoxazone.]
[V04CK02, cholecystokinin, The excretion of Tenofovir alafenamide can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, Ethenzamide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N02BA03, choline salicylate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Vinpocetine.]
[M01AB08, etodolac, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Etodolac.]
[M02AA06, etofenamate, Etofenamate may increase the nephrotoxic activities of Tenofovir alafenamide.]
[B06AC06, berotralstat, The metabolism of Tenofovir alafenamide can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chondroitin sulfate.]
[J05AJ04, cabotegravir, The excretion of Tenofovir alafenamide can be decreased when combined with Cabotegravir.]
[L04AD03, voclosporin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Umbralisib.]
[N03AX10, felbamate, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C01CA19, fenoldopam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fenoldopam.]
[J01DD15, cefdinir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefdinir.]
[R03BA03, flunisolide, The metabolism of Tenofovir alafenamide can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fluocinolone acetonide.]
[S01JA01, fluorescein, The excretion of Tenofovir alafenamide can be decreased when combined with Fluorescein.]
[N02BG07, flupirtine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flupirtine.]
[L01EK03, tivozanib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tivozanib.]
[A02BA01, cimetidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Gabapentin.]
[V08CA04, gadoteridol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gadoteridol.]
[J01MB06, cinoxacin, The excretion of Tenofovir alafenamide can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Tenofovir alafenamide.]
[S03AA07, ciprofloxacin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cisplatin.]
[N06AB04, citalopram, The metabolism of Tenofovir alafenamide can be decreased when combined with Citalopram.]
[L04AA48, belumosudil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The excretion of Tenofovir alafenamide can be decreased when combined with Fexinidazole.]
[L04AA59, avacopan, The metabolism of Tenofovir alafenamide can be decreased when combined with Avacopan.]
[M01AG01, mefenamic acid, Mefenamic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N06AX25, St. John's wort extract, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Tenofovir alafenamide can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clomipramine.]
[N03AE01, clonazepam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Clonazepam.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Tenofovir alafenamide.]
[C01EB24, mavacamten, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oseltamivir.]
[J02AC06, oteseconazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oteseconazole.]
[N05AH02, clozapine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clozapine.]
[A10BK06, sotagliflozin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Arbekacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[H01AC08, somatrogon, The metabolism of Tenofovir alafenamide can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Tenofovir alafenamide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[R05DA04, codeine, The excretion of Tenofovir alafenamide can be decreased when combined with Codeine.]
[M04AC01, colchicine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Colchicine.]
[J01XB01, colistin, Colistin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DE02, cefpirome, Cefpirome may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A04AA03, tropisetron, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tropisetron.]
[C04AX28, ifenprodil, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Ifenprodil.]
[A10BX03, nateglinide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01FA15, telithromycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, Indobufen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J05AB14, valganciclovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Valganciclovir.]
[C05BB03, invert sugar, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Invert sugar.]
[V08AB09, iodixanol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Iodixanol.]
[V08AB05, iopromide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Iopromide.]
[V08AB07, ioversol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ioversol.]
[V08AB12, ioxilan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ioxilan.]
[M01AH03, valdecoxib, Valdecoxib may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N02CC05, almotriptan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S01AD03, acyclovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acyclovir.]
[N05BA10, ketazolam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01EA01, imatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The excretion of Tenofovir alafenamide can be decreased when combined with Esomeprazole.]
[S01EE03, bimatoprost, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bimatoprost.]
[N03AX09, lamotrigine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Lamotrigine.]
[S01BA03, cortisone, The metabolism of Tenofovir alafenamide can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may increase the nephrotoxic activities of Tenofovir alafenamide.]
[M02AA31, loxoprofen, Loxoprofen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01DC08, loracarbef, Loracarbef may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C09AA03, lisinopril, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Magnesium carbonate.]
[C08CA11, manidipine, The metabolism of Tenofovir alafenamide can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Tenofovir alafenamide can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Tenofovir alafenamide can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Meropenem.]
[N05AD03, metylperon, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Melperone.]
[J01FA03, midecamycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Tenofovir alafenamide.]
[S01XA18, cyclosporine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Tenofovir alafenamide can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The excretion of Tenofovir alafenamide can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[M01AX22, morniflumate, Morniflumate may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C03XA02, conivaptan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, Etoricoxib may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01AX04, dacarbazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Tenofovir alafenamide can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Tenofovir alafenamide can be decreased when combined with Daunorubicin.]
[M01AX01, nabumetone, Nabumetone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N07BB05, nalmefene, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nalmefene.]
[S01GX04, nedocromil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nedocromil.]
[N06AX06, nefazodone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nefazodone.]
[C01DX16, nicorandil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nicorandil.]
[L02BB02, nilutamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nilutamide.]
[N03AG06, tiagabine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Tiagabine.]
[B01AX05, fondaparinux, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fondaparinux.]
[A07EC03, olsalazine, Olsalazine may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N06AA01, desipramine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Desmopressin.]
[V04CH02, indigo carmine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Indigotindisulfonic acid.]
[J01DH03, ertapenem, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ertapenem.]
[M01AE12, oxaprozin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Tenofovir alafenamide can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Tenofovir alafenamide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gefitinib.]
[N06BA02, dextroamphetamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amphetamine.]
[N03AC01, paramethadione, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Paramethadione.]
[C01DA05, pentaerythritol tetranitrate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pentaerythritol tetranitrate.]
[P03AC04, permethrin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Permethrin.]
[N05BA01, diazepam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Diazepam.]
[N03AX07, phenacemide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Phenacemide.]
[N03AD02, phensuximide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Phensuximide.]
[R05DA08, pholcodine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pholcodine.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Clodronic acid.]
[S01BC03, diclofenac, Diclofenac may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01CF01, dicloxacillin, The metabolism of Tenofovir alafenamide can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Tenofovir alafenamide is combined with Foscarnet.]
[A03AA07, dicyclomine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dicyclomine.]
[J05AF02, didanosine, The serum concentration of Didanosine can be increased when it is combined with Tenofovir alafenamide.]
[L01DC04, ixabepilone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erlotinib.]
[L02AA01, diethylstilbestrol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Isradipine.]
[D07XC04, diflucortolone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Difluocortolone.]
[N02BA11, diflunisal, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Tenofovir alafenamide.]
[C01AA05, digoxin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Digoxin.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Tenofovir alafenamide.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Tenofovir alafenamide.]
[N02AA03, hydromorphone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Hydromorphone.]
[L04AX04, lenalidomide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lenalidomide.]
[J05AE08, atazanavir, The serum concentration of Atazanavir can be decreased when it is combined with Tenofovir alafenamide.]
[H03BC01, potassium perchlorate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Potassium perchlorate.]
[V03AB04, pralidoxime, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralidoxime.]
[C08DB01, diltiazem, The metabolism of Tenofovir alafenamide can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dimercaprol.]
[M02AX03, dimethyl sulfoxide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Progabide.]
[N02BB04, propyphenazone, Propyphenazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[M01AB14, proglumetacin, Proglumetacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[G02AD02, dinoprostone, The excretion of Tenofovir alafenamide can be decreased when combined with Dinoprostone.]
[C05CA03, diosmin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Diosmin.]
[B01AC07, dipyridamole, The excretion of Tenofovir alafenamide can be decreased when combined with Dipyridamole.]
[A03FA02, cisapride, The metabolism of Tenofovir alafenamide can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Tenofovir alafenamide.]
[S01AX06, resorcinol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Resorcinol.]
[C01BA03, disopyramide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Disopyramide.]
[S02AA12, rifamycin SV, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tenofovir alafenamide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Riluzole.]
[R06AE09, levocetirizine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levocetirizine.]
[N01BB09, ropivacaine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ropivacaine.]
[L01EX01, sunitinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Tenofovir alafenamide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Tenofovir alafenamide.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Tenofovir alafenamide.]
[J05AE07, fosamprenavir, The metabolism of Tenofovir alafenamide can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tadalafil.]
[S01BC05, ketorolac, Ketorolac may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C01EB18, ranolazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may increase the nephrotoxic activities of Tenofovir alafenamide.]
[H05BA01, salmon calcitonin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dobutamine.]
[C01CA04, dopamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dopamine.]
[N06AA12, doxepin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Tenofovir alafenamide.]
[J01AA02, doxycycline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Doxycycline.]
[A08AA10, sibutramine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sibutramine.]
[C10AA01, simvastatin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Simvastatin.]
[A12CA02, sodium sulfate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sodium sulfate.]
[R03DA01, dyphylline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dyphylline.]
[N02CC01, sumatriptan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sumatriptan.]
[V04CX07, edrophonium, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Edrophonium.]
[H01AA01, corticotropin, The metabolism of Tenofovir alafenamide can be increased when combined with Corticotropin.]
[J01CG02, tazobactam, The excretion of Tenofovir alafenamide can be decreased when combined with Tazobactam.]
[L01AX03, temozolomide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Temozolomide.]
[M01AC02, tenoxicam, Tenoxicam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[D01BA02, terbinafine, The metabolism of Tenofovir alafenamide can be increased when combined with Terbinafine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Tenofovir alafenamide.]
[C09AA02, enalapril, The excretion of Tenofovir alafenamide can be decreased when combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N06AG03, toloxatone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Toloxatone.]
[N06BA09, atomoxetine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Atomoxetine.]
[N03AX11, topiramate, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Toremifene.]
[N05CC01, chloral hydrate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Chloral hydrate.]
[D03AX12, triethanolamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trolamine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Tenofovir alafenamide.]
[N06AX16, venlafaxine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Tenofovir alafenamide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Tenofovir alafenamide can be decreased when combined with Epinephrine.]
[M01AB04, zomepirac, Zomepirac may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N03AX15, zonisamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Zonisamide.]
[L01XA02, carboplatin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Carboplatin.]
[C02AC02, guanfacine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Guanfacine.]
[N02CA02, ergotamine, The metabolism of Tenofovir alafenamide can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pidotimod.]
[S01AA17, erythromycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Estazolam.]
[A02BC02, pantoprazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pantoprazole.]
[G03CA03, estradiol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Tenofovir alafenamide can be increased when it is combined with Conjugated estrogens.]
[G03CC04, estrone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Estrone.]
[J04AK02, ethambutol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Tenofovir alafenamide can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Tenofovir alafenamide can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The excretion of Tenofovir alafenamide can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gadodiamide.]
[C01BD05, ibutilide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ibutilide.]
[N03AD01, ethosuximide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Ethosuximide.]
[N03AB01, ethotoin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Ethotoin.]
[M01AC06, meloxicam, Meloxicam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N01AX07, etomidate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Etomidate.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Tenofovir alafenamide.]
[L04AD02, tacrolimus, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tacrolimus.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Tenofovir alafenamide.]
[R06AX12, terfenadine, The metabolism of Tenofovir alafenamide can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trimetrexate.]
[N06AX12, bupropion, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bupropion.]
[N06AB08, fluvoxamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fluvoxamine.]
[L02AE02, leuprolide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sodium aurothiomalate.]
[B05AA05, dextran, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dextran.]
[V03AF02, dexrazoxane, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexrazoxane.]
[A02BA03, famotidine, The excretion of Tenofovir alafenamide can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Albendazole.]
[N03AX26, fenfluramine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N02AB03, fentanyl, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fentanyl.]
[R03CC02, albuterol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clofarabine.]
[N07AX03, cevimeline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cevimeline.]
[G04BD02, flavoxate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flavoxate.]
[N02BG04, floctafenine, Floctafenine may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J01CF05, floxacillin, The metabolism of Tenofovir alafenamide can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flucytosine.]
[V03AB25, flumazenil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flumazenil.]
[N07CA03, flunarizine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Flunarizine.]
[D07AC08, fluocinonide, The metabolism of Tenofovir alafenamide can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Tenofovir alafenamide can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Tenofovir alafenamide can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Floxuridine.]
[N06AB03, fluoxetine, The metabolism of Tenofovir alafenamide can be decreased when combined with Fluoxetine.]
[N05CD01, flurazepam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flurbiprofen.]
[L02BB01, flutamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Flutamide.]
[V04CX02, folic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Folic acid.]
[S02AA17, fosfomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fosfomycin.]
[S01AA07, framycetin, Framycetin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01BC03, tegafur, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tegafur.]
[C03CA01, furosemide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Alendronic acid.]
[N05CF04, eszopiclone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Eszopiclone.]
[S01AD09, ganciclovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ganciclovir.]
[N03AA04, barbexaclone, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Barbexaclone.]
[C10AB04, gemfibrozil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gemfibrozil.]
[J01XA03, telavancin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Telavancin.]
[L01EA02, dasatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Tenofovir alafenamide.]
[J05AG04, etravirine, The metabolism of Tenofovir alafenamide can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Methsuximide.]
[L01EH01, lapatinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The excretion of Tenofovir alafenamide can be decreased when combined with Glyburide.]
[A10BB07, glipizide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glipizide.]
[N05CM18, dexmedetomidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexmedetomidine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Tenofovir alafenamide.]
[C02CA04, doxazosin, The metabolism of Tenofovir alafenamide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sorafenib.]
[M01CB04, aurothioglucose, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Aurothioglucose.]
[S01LA03, pegaptanib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pegaptanib.]
[C09AA09, fosinopril, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Tenofovir alafenamide can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Guanethidine.]
[L02AE03, goserelin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Goserelin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Tenofovir alafenamide.]
[N05AH04, quetiapine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Quetiapine.]
[N06BX13, idebenone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Idebenone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Tenofovir alafenamide.]
[M04AA01, allopurinol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Allopurinol.]
[C09CA01, losartan, The metabolism of Tenofovir alafenamide can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tenofovir alafenamide.]
[C01CE02, milrinone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Milrinone.]
[N05CA16, hexobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Hexobarbital.]
[C08CA10, nilvadipine, The metabolism of Tenofovir alafenamide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C09AA04, perindopril, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Perindopril.]
[C02DB02, hydralazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S02BA01, hydrocortisone, The metabolism of Tenofovir alafenamide can be increased when combined with Hydrocortisone.]
[B05XA17, potassium acetate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Potassium acetate.]
[V03AB33, hydroxocobalamin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Hydroxocobalamin.]
[G04BD06, propiverine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Propiverine.]
[B05AA07, hetastarch, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Hydroxyethyl Starch.]
[J04AB04, rifabutin, The metabolism of Tenofovir alafenamide can be increased when combined with Rifabutin.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Risedronic acid.]
[R02AX02, ibuprofen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ibuprofen.]
[B05XA08, sodium acetate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sodium acetate.]
[L01AA06, ifosfamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Tenofovir alafenamide.]
[R01AD07, tixocortol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tixocortol.]
[M03BX02, tizanidine, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Tizanidine.]
[L01CE01, topotecan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Topotecan.]
[C03BA11, indapamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Indapamide.]
[S01BC01, indomethacin, Indomethacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A11HA07, inositol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Inositol.]
[N06AX17, milnacipran, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Varenicline.]
[A10BH01, sitagliptin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alprazolam.]
[N05CH02, ramelteon, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ramelteon.]
[C10AA06, cerivastatin, The metabolism of Tenofovir alafenamide can be increased when combined with Cerivastatin.]
[V03AB01, ipecac, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ipecac.]
[G04BE01, alprostadil, The excretion of Tenofovir alafenamide can be decreased when combined with Alprostadil.]
[J04AC01, isoniazid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Isoniazid.]
[J05AX05, inosine pranobex, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Inosine pranobex.]
[C01DA14, isosorbide mononitrate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Isosorbide mononitrate.]
[D10BA01, isotretinoin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Isotretinoin.]
[P02CF01, ivermectin, The excretion of Tenofovir alafenamide can be decreased when combined with Ivermectin.]
[S01AA24, kanamycin, Kanamycin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L04AC07, tocilizumab, The metabolism of Tenofovir alafenamide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ketamine.]
[B01AC22, prasugrel, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Prasugrel.]
[H02CA04, levoketoconazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levoketoconazole.]
[M02AA10, ketoprofen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Tenofovir alafenamide can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Tenofovir alafenamide can be increased when combined with Abatacept.]
[D10AX03, azelaic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Azelaic acid.]
[J01MB02, nalidixic acid, The excretion of Tenofovir alafenamide can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C07AG01, labetalol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Labetalol.]
[N04BB01, amantadine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amantadine.]
[A06AX03, lubiprostone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lubiprostone.]
[N03AX18, lacosamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S01AA21, amikacin, Amikacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N06BA13, armodafinil, The metabolism of Tenofovir alafenamide can be increased when combined with Armodafinil.]
[N05BA06, lorazepam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Tenofovir alafenamide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Loxapine.]
[D06BA03, mafenide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mafenide.]
[L01EG01, temsirolimus, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Magnesium chloride.]
[G04BX01, magnesium hydroxide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Magnesium hydroxide.]
[V04CC02, magnesium sulfate, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Maprotiline.]
[C02BB01, mecamylamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Meclofenamic acid.]
[N05BA03, medazepam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Medazepam.]
[P01BC02, mefloquine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mefloquine.]
[N05CH01, melatonin, The excretion of Tenofovir alafenamide can be decreased when combined with Melatonin.]
[N06DX01, memantine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Memantine.]
[N02AB02, meperidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Meperidine.]
[N03AB04, mephenytoin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Mephenytoin.]
[N03AA01, mephobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mepivacaine.]
[G04BX16, tiopronin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tiopronin.]
[L02BG01, aminoglutethimide, The metabolism of Tenofovir alafenamide can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mersalyl.]
[N05AX13, paliperidone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metformin.]
[H01CB03, lanreotide, The metabolism of Tenofovir alafenamide can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methadone.]
[N06BA03, methamphetamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metamfetamine.]
[J05AF05, lamivudine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Lamivudine.]
[N03AA30, metharbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Metharbital.]
[S01EC05, methazolamide, The excretion of Tenofovir alafenamide can be decreased when combined with Methazolamide.]
[H03BB02, methimazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pemetrexed.]
[N05CA15, methohexital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Methohexital.]
[A11HA02, pyridoxine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pyridoxine.]
[L04AX03, methotrexate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methotrexate.]
[D05BA02, methoxsalen, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methoxsalen.]
[C02AB01, methyldopa, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methyldopa.]
[V04CG05, methylene blue, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Tenofovir alafenamide can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Tenofovir alafenamide.]
[H02AB04, methylprednisolone, The metabolism of Tenofovir alafenamide can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Rufinamide.]
[G03EK01, methyltestosterone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methyltestosterone.]
[N02CA04, methysergide, The metabolism of Tenofovir alafenamide can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metoclopramide.]
[C03BA08, metolazone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metolazone.]
[C07AB02, metoprolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Tenofovir alafenamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[G03XB01, mifepristone, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Mifepristone.]
[J05AH01, zanamivir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Zanamivir.]
[C09CA03, valsartan, The excretion of Tenofovir alafenamide can be decreased when combined with Valsartan.]
[J01AA08, minocycline, The excretion of Tenofovir alafenamide can be decreased when combined with Minocycline.]
[J01FA11, miocamycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Tenofovir alafenamide can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amitriptyline.]
[A04AA05, palonosetron, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L04AB05, certolizumab pegol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Eltrombopag.]
[G04BA01, ammonium chloride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Tenofovir alafenamide.]
[L04AA06, mycophenolic acid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Amobarbital.]
[G03XC01, raloxifene, The metabolism of Tenofovir alafenamide can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nadolol.]
[J01CA04, amoxicillin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amoxicillin.]
[J01CF06, nafcillin, The metabolism of Tenofovir alafenamide can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Tenofovir alafenamide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amphetamine.]
[M02AA12, naproxen, Naproxen may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A10BG01, troglitazone, The metabolism of Tenofovir alafenamide can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Duloxetine.]
[N04BX01, tolcapone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tolcapone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Tenofovir alafenamide.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Tenofovir alafenamide is combined with Neomycin.]
[B01AC17, tirofiban, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tirofiban.]
[J02AA01, amphotericin B, Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S01AA19, ampicillin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ampicillin.]
[L03AX16, plerixafor, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Plerixafor.]
[S01AA23, netilmicin, Netilmicin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N06AX23, desvenlafaxine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Telmisartan.]
[J05AB11, valacyclovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Valaciclovir.]
[M04AA03, febuxostat, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Febuxostat.]
[C01CE01, inamrinone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amrinone.]
[C10AD02, niacin, The metabolism of Tenofovir alafenamide can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Tenofovir alafenamide can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[C08CA07, nisoldipine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nisoldipine.]
[N05CD02, nitrazepam, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Nitrazepam.]
[R07AX01, nitric oxide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Zaleplon.]
[N04BC05, pramipexole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pramipexole.]
[C02DD01, nitroprusside, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nitroprusside.]
[G03DC02, norethindrone, The metabolism of Tenofovir alafenamide can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The excretion of Tenofovir alafenamide can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Tenofovir alafenamide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Tenofovir alafenamide.]
[R05DA07, noscapine, The metabolism of Tenofovir alafenamide can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sapropterin.]
[G01AA01, nystatin, The excretion of Tenofovir alafenamide can be decreased when combined with Nystatin.]
[H01CB02, octreotide, The metabolism of Tenofovir alafenamide can be decreased when combined with Octreotide.]
[S02AA16, ofloxacin, The excretion of Tenofovir alafenamide can be decreased when combined with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Tenofovir alafenamide can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Tenofovir alafenamide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Omeprazole.]
[N02AA02, opium, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Opium.]
[G04CA02, tamsulosin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tamsulosin.]
[C01AC01, ouabain, The excretion of Tenofovir alafenamide can be decreased when combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Zoledronic acid.]
[J01CF04, oxacillin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oxacillin.]
[N05BA04, oxazepam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Oxazepam.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[S01AA04, oxytetracycline, The excretion of Tenofovir alafenamide can be decreased when combined with Oxytetracycline.]
[V04CH30, 4-aminohippuric acid, The excretion of Tenofovir alafenamide can be decreased when combined with Aminohippuric acid.]
[J04AB30, capreomycin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capreomycin.]
[N05CC05, paraldehyde, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Tenofovir alafenamide can be increased when combined with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[G04BD11, fesoterodine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Penbutolol.]
[S01AA14, penicillin G, The excretion of Tenofovir alafenamide can be decreased when combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Procaine benzylpenicillin.]
[N05CA01, pentobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Pentobarbital.]
[L01XX08, pentostatin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pentostatin.]
[C04AD03, pentoxifylline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pentoxifylline.]
[N02BE03, phenacetin, The excretion of Tenofovir alafenamide can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Phenazopyridine.]
[N06AF03, phenelzine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Phenelzine.]
[N03AA02, phenobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Tenofovir alafenamide.]
[V03AB36, phentolamine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N03AB02, phenytoin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Tenofovir alafenamide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Tenofovir alafenamide.]
[B02BA01, vitamin K1, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Phylloquinone.]
[J05AB12, cidofovir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cidofovir.]
[C08CX01, mibefradil, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Tenofovir alafenamide.]
[C07AA03, pindolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pindolol.]
[C10AA05, atorvastatin, The excretion of Tenofovir alafenamide can be decreased when combined with Atorvastatin.]
[J01CA12, piperacillin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Piperacillin.]
[J05AE01, saquinavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Piracetam.]
[S01BC06, piroxicam, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may increase the nephrotoxic activities of Tenofovir alafenamide.]
[J05AG02, delavirdine, The metabolism of Tenofovir alafenamide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Tenofovir alafenamide can be decreased when combined with Irbesartan.]
[A10BG02, rosiglitazone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rosiglitazone.]
[L04AC08, canakinumab, The metabolism of Tenofovir alafenamide can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Tenofovir alafenamide is combined with Polymyxin B.]
[J05AE03, ritonavir, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Saxagliptin.]
[B05XA01, potassium chloride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Potassium chloride.]
[C10AA08, pitavastatin, The excretion of Tenofovir alafenamide can be decreased when combined with Pitavastatin.]
[S03BA02, prednisolone, The metabolism of Tenofovir alafenamide can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Prednisone.]
[P01BA03, primaquine, The metabolism of Tenofovir alafenamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Procainamide.]
[C10AB05, fenofibrate, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fenofibrate.]
[G03DA04, progesterone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Progesterone.]
[R06AD02, promethazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Promethazine.]
[C01BC03, propafenone, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Propantheline.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Tenofovir alafenamide.]
[N01AX10, propofol, The metabolism of Tenofovir alafenamide can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Tenofovir alafenamide can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Propranolol.]
[N02CC04, rizatriptan, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rizatriptan.]
[B01AC09, epoprostenol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Epoprostenol.]
[N07XX07, dalfampridine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dalfampridine.]
[P02CC01, pyrantel, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pyrantel.]
[J04AK01, pyrazinamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pyrazinamide.]
[C01BA01, quinidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ribavirin.]
[S01XA26, riboflavin, The excretion of Tenofovir alafenamide can be decreased when combined with Riboflavin.]
[J04AB02, rifampin, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The excretion of Tenofovir alafenamide can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A07EC01, sulfasalazine, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulfasalazine.]
[S01BC08, salicylic acid, Salicylic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[N05CA06, secobarbital, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Secobarbital.]
[J01GB08, sisomicin, Sisomicin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[A12CD01, sodium fluoride, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sodium fluoride.]
[H01CB01, somatostatin, The metabolism of Tenofovir alafenamide can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sorbitol.]
[L01CD04, cabazitaxel, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cabazitaxel.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Tenofovir alafenamide.]
[V09AB03, ioflupane I-123, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ioflupane I-123.]
[V09AA01, technetium Tc 99m exametazime, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Technetium Tc-99m exametazime.]
[V09AX06, florbetaben f-18, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Florbetaben (18F).]
[N03AG01, valproic acid, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Valproic acid.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Etidronic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Tenofovir alafenamide can be increased when combined with Hydrocortisone butyrate.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Emtricitabine which could result in a higher serum level.]
[C08DA01, verapamil, The excretion of Emtricitabine can be decreased when combined with Verapamil.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Emtricitabine.]
[L01ED04, brigatinib, The excretion of Emtricitabine can be decreased when combined with Brigatinib.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Emtricitabine.]
[J01GB14, plazomicin, The excretion of Emtricitabine can be decreased when combined with Plazomicin.]
[P01BA07, tafenoquine, The excretion of Emtricitabine can be decreased when combined with Tafenoquine.]
[L01EX13, gilteritinib, The excretion of Emtricitabine can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The excretion of Emtricitabine can be decreased when combined with Glasdegib.]
[N06BA14, solriamfetol, The excretion of Solriamfetol can be decreased when combined with Emtricitabine.]
[L01EX15, pexidartinib, The excretion of Emtricitabine can be decreased when combined with Pexidartinib.]
[L01EJ02, fedratinib, The excretion of Emtricitabine can be decreased when combined with Fedratinib.]
[N04CX01, istradefylline, The excretion of Emtricitabine can be decreased when combined with Istradefylline.]
[J01DB01, cephalexin, The excretion of Emtricitabine can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The excretion of Cefradine can be decreased when combined with Emtricitabine.]
[L01XX72, tazemetostat, The excretion of Emtricitabine can be decreased when combined with Tazemetostat.]
[J05AB16, remdesivir, The excretion of Emtricitabine can be decreased when combined with Remdesivir.]
[L01EH03, tucatinib, The excretion of Emtricitabine can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Emtricitabine can be decreased when combined with Capmatinib.]
[L01EX19, ripretinib, The excretion of Emtricitabine can be decreased when combined with Ripretinib.]
[L01EX22, selpercatinib, The excretion of Emtricitabine can be decreased when combined with Selpercatinib.]
[M09AX10, risdiplam, The serum concentration of Emtricitabine can be increased when it is combined with Risdiplam.]
[L01EX23, pralsetinib, The excretion of Emtricitabine can be decreased when combined with Pralsetinib.]
[V03AF12, trilaciclib, The excretion of Emtricitabine can be decreased when combined with Trilaciclib.]
[A02BA01, cimetidine, The excretion of Emtricitabine can be decreased when combined with Cimetidine.]
[S03AA07, ciprofloxacin, The excretion of Emtricitabine can be decreased when combined with Ciprofloxacin.]
[P01CA03, fexinidazole, The excretion of Emtricitabine can be decreased when combined with Fexinidazole.]
[J05AB14, valganciclovir, The risk or severity of cytopenia can be increased when Valganciclovir is combined with Emtricitabine.]
[S01AD03, acyclovir, The excretion of Emtricitabine can be decreased when combined with Acyclovir.]
[N07BC04, lofexidine, The excretion of Emtricitabine can be decreased when combined with Lofexidine.]
[S02AA12, rifamycin SV, The excretion of Emtricitabine can be decreased when combined with Rifamycin.]
[C01EB18, ranolazine, The excretion of Emtricitabine can be decreased when combined with Ranolazine.]
[A02BA03, famotidine, The excretion of Emtricitabine can be decreased when combined with Famotidine.]
[C01BC04, flecainide, The excretion of Flecainide can be decreased when combined with Emtricitabine.]
[S01AD09, ganciclovir, The risk or severity of cytopenia can be increased when Ganciclovir is combined with Emtricitabine.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Emtricitabine.]
[A10BA02, metformin, The excretion of Emtricitabine can be decreased when combined with Metformin.]
[V04CG05, methylene blue, The excretion of Emtricitabine can be decreased when combined with Methylene blue.]
[C07AA12, nadolol, The excretion of Nadolol can be decreased when combined with Emtricitabine.]
[S01AE05, levofloxacin, The excretion of Levofloxacin can be decreased when combined with Emtricitabine.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Emtricitabine.]
[P01BD01, pyrimethamine, The excretion of Emtricitabine can be decreased when combined with Pyrimethamine.]
[J05AP01, ribavirin, Ribavirin may increase the hepatotoxic activities of Emtricitabine.]
[H02CA04, levoketoconazole, The excretion of Emtricitabine can be decreased when combined with Levoketoconazole.]
